MAPT Antisense Oligonucleotide Sequences for Tauopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no FDA-approved disease-modifying therapeutic agent specifically for reducing MAPT expression to treat tauopathies such as Alzheimer's disease and frontotemporal dementia.
Innovation Solution
Development of MAPT antisense oligonucleotides with specific nucleic acid sequences and modifications, administered via various routes, to target and reduce MAPT expression, thereby treating tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are used to reduce MAPT expression, then therapeutic efficacy for tauopathies is improved, but no FDA-approved disease-modifying therapeutic agent currently exists for this indication
Solution Approach 1:
The patent applies parameter changes by systematically modifying oligonucleotide characteristics including sequence composition (SEQ ID NOs: 1-11, 30-32, 36-63), chemical modifications (2′-O-MOE, LNA, phosphorothioate linkages), and structural features (gapmer configuration) to optimize therapeutic efficacy while navigating regulatory requirements for FDA approval of disease-modifying therapies
2Reliability
If modified nucleotides and internucleotide linkages are incorporated into antisense oligonucleotides, then stability and efficacy are improved, but molecular complexity increases
Solution Approach 1:
The patent applies local quality by implementing site-specific modifications within the oligonucleotide structure, including placing 2′-O-MOE or LNA modifications at specific positions (e.g., 5′ and 3′ wings of gapmers), incorporating phosphorothioate linkages at particular internucleotide positions, and maintaining unmodified regions to balance stability enhancement with manufacturability and reduce unnecessary complexity
Solution Approach 2:
The patent applies composite materials by combining multiple modification types within a single oligonucleotide molecule, creating composite structures that integrate different chemistries (e.g., LNA-modified regions combined with phosphorothioate linkages, or 2′-O-MOE modifications with gapmer architecture) to achieve synergistic effects for enhanced stability and efficacy
3Adaptability or versatility
If multiple Tau isoforms exist with different splicing patterns, then biological functionality is improved, but target specificity for antisense oligonucleotides becomes more challenging
Solution Approach 1:
The patent applies local quality by designing antisense oligonucleotides that target specific local regions within the MAPT transcript, such as exon-specific sequences or splice junctions, allowing selective modulation of particular Tau isoforms (e.g., 3R vs 4R, 0N vs 2N) while preserving others, thereby achieving isoform-specific therapy through localized target engagement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MAPT antisense oligonucleotides effectively reduce MAPT expression, providing a therapeutic approach for tauopathies by targeting the underlying cause of these neurodegenerative disorders.
Implementation Method 1
An antisense oligonucleotide usually comprises a nucleic acid sequence that is complementary to a corresponding segment of a target nucleic acid
Implementation Method 2
When an antisense oligonucleotide comprising a contiguous stretch of DNA hybridizes with a target RNA, the DNA-RNA heteroduplex recruit RNase H, which cleaves the target RNA
Data Source
AI summary
Provided herein are MAPT antisense oligonucleotides and compositions comprising a MAPT antisense oligonucleotide. Also provided herein are methods of using the MAPT antisense oligonucleotides or compositions comprising a MAPT antisense oligonucleotide for reducing MAPT expression and/or treating tauopathy in a subject.